跳至主要内容
临床试验/IRCT20230517058211N1
IRCT20230517058211N1招募中3 期

Comparison of efficacy and safety of intravenous cyclophosphamide and steroids with oral cyclophosphamide and steroids in the treatment of idiopathic membranous nephropathy

Jinnah Hospital/ Allama Iqbal Medical College0 个研究点目标入组 58 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
58

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • Serum Anti-Phospho Lipase A2 Receptor positive or IgG4 positivity on Immunofluorescence.
  • Biopsy –proven Idiopathic Membranous Nephropathy, moderate risk group (Spot Urine protein/ spot urine creatinine Ratio between 4 to 8 g/g) that has failed to respond to conservative therapy for 6 months.
  • Biopsy–proven Idiopathic Membtanous Nephropathy high risk group (Spot Urine protein/ spot urine creatinine Ratio more than 8g/g).

排除标准

  • Patients with clinical, histologic, or serologic evidence of secondary Membranous Nephropathy.
  • Evidence of Hepatitis B/C and Human Immunodeficiency Virus
  • Evidence of malignancy (Prostate Specific Antigen, Mammogram, Chest x-ray.)
  • Active or ongoing infection/ Recent infection.
  • Allergy to cyclophosphamide.
  • Contraindication to steroid/ cyclophosphamide

研究者

相似试验